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ABSTRACT:  27 
Introduction: Assessment of Human papillomavirus (HPV) prevalence and genotype distribution is 28 
important for monitoring the impact of prophylactic HPV vaccination. This study aimed to 29 
demonstrate the HPV genotypes predominating in pre-malignant and cervical cancers in Northern 30 
Ireland (NI) before the vaccination campaign has effect.  31 
Methods: Formalin fixed paraffin embedded tissue blocks from 2,303 women aged 16-93 years 32 
throughout NI were collated between April 2011 and February 2013. HPV DNA was amplified by PCR 33 
and HPV genotyping undertaken using the Roche® linear array detection kit.  34 
Results: In total, 1,241 out of 1,830 eligible samples (68.0%) tested positive for HPV, with the 35 
majority of these [1,181/1,830 (64.5%)] having high-risk (HR) HPV infection; 37.4% were positive for 36 
HPV-16 (n=684) and 5.1% for HPV-18 (n=93). HPV type-specific prevalence was 48.1%, 65.9%, 81.3%, 37 
92.2% and 64.3% among cervical intraepithelial neoplasias (CIN) grades I-III, squamous cell 38 
carcinomas (SCC) and adenocarcinoma (AC) cases, respectively. Most SCC cases (81.3%) had only one 39 
HPV genotype detected and almost a third (32.0%) of all cervical pathologies were HPV negative 40 
including 51.9% of CIN I (n=283), 34.1% CIN II (n=145), 18.7% of CIN III (n=146), 7.8% of SCC (n=5) 41 
and 35.7% of AC (n=5) cases. 42 
Conclusions: This study provides important baseline data for monitoring the effect of HPV 43 
vaccination in NI and for comparison with other UK regions. The coverage of other HR-HPV 44 
genotypes apart from 16 and 18, including HPV-45, 31, 39 and 52, and the potential for cross 45 
protection, should be considered when considering future polyvalent vaccines.  46 
 47 
Keywords: human papillomavirus, cervical cancer, cervical intraepithelial neoplasia, frequency, 48 
population-based.  49 
 50 
 51 
 52 
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INTRODUCTION 53 
Annually 3,000 women are diagnosed with, and almost 1,000 die from cervical cancer in the United 54 
Kingdom (UK), making it the 12th most common cancer diagnosis and 17th most common cancer 55 
death [Cancer Research UK, 2014]. Two main subtypes exist, squamous cell carcinoma (SCC) and 56 
adenocarcinoma (AC). Persistent infection with high-risk (HR) oncogenic human papillomavirus 57 
(HPV) family alpha-Papillomaviridae is a necessary, but insufficient cause, for invasive cervical cancer 58 
[IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., 2012]; with HPV-16 and 59 
HPV-18, the most common oncogenic types, contributing to around 70% of all cases worldwide 60 
[WHO/ICO Information Centre on HPV and Cervical Cancer, 2010].  61 
 62 
HPV is highly sexually transmissible with 80% of women expected to have a HPV infection at some 63 
point during their sexually active life [Alexander et al, 2012]. Many women are repeatedly infected, 64 
with most infections occurring in those aged under 25 years [de Sanjosé et al, 2007; Smith et al, 65 
2008; Anderson et al, 2013]. However, despite frequent exposure to HPV, development of cervical 66 
cancer is uncommon with most HPV infections being transient and spontaneously regressing within 67 
two years with no residual abnormality [Castellsagué, 2008]. In some cases HPV infection may 68 
persist [Trottier et al, 2009], with some HPV genotypes more persistent than others [Louvanto et al, 69 
2010]. Recent studies indicate a higher proportion of CIN II and CIN III lesions progressing to invasive 70 
cancer in HPV-16 positive lesions, often within as little as 10-20 years [Jaisamrarn et al, 2013; Vink et 71 
al, 2013; Wentzensen et al, 2013]. Many aspects of the natural history of HPV infection remain to be 72 
fully elucidated, including the probable existence of latent infections and potential reactivation.  73 
 74 
Although HPV-16, 18, 31, 52 and 58 are cited among the top 10 most common HPV genotypes 75 
worldwide [Bruni et al, 2010], there is significant variation in the reported prevalence of HR-HPV 76 
genotypes between countries. We previously reported that the prevalence of any HPV infection in 77 
Northern Ireland (NI) women having a pap smear was 17.1%,  ranging from 42.5% in those aged 20-78 
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24 years to 4.2% in women aged 60-64 years; HPV prevalence was lower in women with normal 79 
cytology at 13.2% increasing in those with cervical disease [Anderson et al, 2013]. However, this 80 
study was underpowered to detect the prevalence of HPV genotypes in high-grade cervical 81 
abnormalities (n=72).    82 
 83 
The aim of the present study was therefore to provide an estimate of the background prevalence of 84 
HPV infection and age-specific HPV type distribution, and to highlight the HPV genotypes most 85 
frequently present in cervical cancer tissue and precursor lesions, before the HPV vaccination 86 
programme alters the distribution of HPV infection in NI. Of note, unpublished data from the present 87 
study has been recently incorporated into a pooled analysis of the HPV type-specific prevalence in 88 
invasive cervical cancers in the UK [Mesher et al, 2014] where the overall prevalence of any HR-HPV 89 
was found to be 95.8%; data that will be valuable in future HPV vaccine monitoring and effectiveness 90 
studies. More detailed data on the prevalence of all detected HPV genotypes stratified by five year 91 
age-bands, inclusive of CIN I-III and cervical pathologies are reported herein. 92 
 93 
 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
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METHODS 105 
Sample selection 106 
Prospectively derived formalin fixed paraffin embedded (FFPE) cervical tissue blocks (processed at all 107 
four pathology laboratories in NI) pertaining to routine diagnostic samples collected between April 108 
2011 and February 2013 from all women attending for cervical screening across NI (population-109 
based cohort), and which were determined to have cervical abnormalities, were eligible for 110 
inclusion. No age or histological restrictions were applied to the cohort during specimen collection.  111 
 112 
Through data supplied by the Public Health Agency Northern Ireland, we estimate that only a small 113 
proportion of samples may have been derived from previously HPV vaccinated women (5.9%), thus 114 
the majority of samples included in this study are from HPV unvaccinated women. Following routine 115 
examination of the biopsy in each reporting laboratory, consultant pathologists selected the most 116 
appropriate FFPE block containing the highest grade of disease reported.  The selected cervical 117 
tissue blocks were sent to the Department of Cellular & Molecular Pathology, Northern Health & 118 
Social Care Trust for HPV determination. For the purposes of the present study, analysis was 119 
restricted to samples identified as cervical intraepithelial neoplasia (CIN) grades I, II and III, SCC and 120 
AC. On reception of the FFPE tissue blocks, pathology records were accessed and clinical pathological 121 
information including patient age, sample type and histology, were extracted. A unique study 122 
number was then assigned to each case and the link to the original case broken, ensuring 123 
confidentiality and complete anonymisation of the results. Ethical approval for the study was 124 
granted from the Office of Research Ethics Committees NI (ORECNI ref: 08/NIIR02/104).  125 
 126 
Specimen processing  127 
FFPE tissue blocks underwent tissue microtomy and were processed under molecular pathology 128 
conditions, to reduce the risk of cross contamination. Tissue lysis was performed using the QIAGEN 129 
ATL (EDTA and 10% sodium dodecyl sulphate) buffer (P/N 19076, Qiagen, Crawly, West Sussex, UK), 130 
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in the presence of 20µl of proteinase K (P/N 19131, Qiagen, Crawley, West Sussex, UK). The tissue 131 
was incubated at 56C ± 2C for 24 hours with occasional vortex mixing during this incubation 132 
period. During post enzymatic incubation, the lysate was added to processing tubes and was 133 
subjected to automated DNA extraction on the Roche COBAS® 480 X module as per manufactures 134 
protocols. Extracted DNA was eluted into buffer EB and stored at -20oC until amplification. Detection 135 
of HPV genotypes were undertaken using a modified Roche Linear Array HPV genotyping test (LA 136 
HPV GT P/N:04391853 190) and the Linear Array detection kit (LA DK P/N: 03378179 190, Roche 137 
Molecular Systems, Inc. Branchburg, NJ, USA). The modification from manufactures protocol 138 
consisted of the addition of a compound into the HPV MasterMix, to allow for compatibility with the 139 
DNA extracted from the COBAS® 480 X module. Extracted DNA was quantified via NanoDrop 140 
spectrophotometry with all samples standardised to a concentration of 24ng/ul; the optimum level 141 
determined in-house to allow for successful HPV detection in the background of human DNA and 142 
reduce the number of test failures due to an “overloaded” PCR reaction.  Of note, the Roche linear 143 
array uses multiple type (mixed) probes to detect DNA from HPV-52 which limits the assay’s ability 144 
to discriminate HPV-52 status in the presence of HPV 33, 35 and/or 58 infections. The HPV-52 145 
genotype was thus derived as positive if co-infection of HPV 33, 35 and 58 was not present in the 146 
sample. Cervical SCC samples that tested HPV negative were revisited, DNA isolated and retested to 147 
ensure the result. Samples were considered HPV negative only when a linear array negative result 148 
was obtained and confirmed by repeat testing.  149 
 150 
Specimen Reporting 151 
The term HR-HPV is used to describe a number of HPV genotypes that have been shown to be 152 
associated with an increased risk of cervical cancer and include: HPV-16, 18, 31, 33, 35, 39, 45, 51, 153 
52, 56, 58, 59 (carcinogenic), 68 (probably carcinogenic) and 66 (possibly carcinogenic) based on the 154 
World Health Organization (WHO) HPV categorizations [Cogliano et al, 2005]. The term ‘low-risk 155 
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HPV’ covers all other HPV genotypes detected by the Roche HPV linear array genotyping test. All 156 
HPV types identified by the Roche linear array are shown in Table 3.  157 
 158 
Statistical analysis 159 
The overall prevalence, genotype and age-specific HPV prevalence among pre-malignant lesions (CIN 160 
I-III) and cervical cancers (SSC and AC) were estimated for all samples. The frequency of those testing 161 
positive for HPV-16 and HPV-18 with or without other HR-HPV genotypes was investigated. Women 162 
within the study were stratified into five year age bands, this was further classified into three age 163 
groups for the following reasons; under 25 years (outside the age range for the current NI Cervical 164 
Screening Programme, but current at the time of our previous prevalence study in the screened 165 
population); 25 to 34 years (reported to have a higher transient HPV infection risk with no significant 166 
underlying disease [Khan et al, 2005]), over 35 years (this group of HR-HPV positive is said to have a 167 
higher chance of significant pathological outcome [Khan et al, 2005]). STATA IC/11.2 (StataCorp, 168 
College Station, TX, USA) was used for all analyses.  169 
 170 
 171 
 172 
 173 
 174 
 175 
 176 
 177 
 178 
 179 
 180 
 181 
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RESULTS 182 
In total, 2,303 samples were received between April 2011 and February 2013. Figure 1 is a flow 183 
diagram providing justification for the selection of study samples. Exclusions included 58 samples 184 
that were not tested due to overrepresentation in the low-grade dyskaryosis groups, a further 200 185 
were excluded at the post-analytical phase of the study due to insufficient tissue remaining for 186 
molecular analysis. 218 samples were also excluded as they were not SCC, AC or CIN I-III pathologies. 187 
A total of 1,827 eligible samples were included for analysis, the majority of which were acquired 188 
through large loop excisions of the transformation zone (64.8%) or punch biopsies (34.2%).  189 
 190 
Prevalence of HPV infection:  191 
In total, 1,243/1,827 samples (68.0%) tested positive for HPV, with the majority 1,183/1,827 (64.8%) 192 
having HR-HPV infection. A total of 584/1,827 (32.0%) of samples were HPV negative, 37.4% were 193 
positive for HPV-16 (n=684) and 5.1% for HPV-18 DNA (n=93). Figure 2 outlines the overall HPV 194 
genotype profile among the cohort and HPV multiplicity. The five most common HPV genotypes 195 
detected across all cervical pathologies examined were HPV-16 (n=684), HPV-31 (n=150), HPV-52 196 
(n=125), HPV-18 (n=93) and HPV-33 (n=91) (Figure 2).  197 
 198 
HPV type-specific prevalence:  199 
The majority of samples were from CIN III cases (42.6%). HPV DNA was detected in 262/545 (48.1%) 200 
of CINI samples, 280/425 (65.9%) of CIN II lesions, 633/779 (81.3%) of CIN III specimens, 59/64 201 
(92.2%) of SCCs and 9/14 (64.3%) of AC samples. Table 1 details the number of HPV genotypes 202 
detected by pathological subtype. Half of all samples (49.7%) had only one HPV genotype detected 203 
(n=908). Multiple HPV genotypes (>1) were more common in CIN I-III lesions than other cervical 204 
pathologies. Among SCC specimens, 7.8% had no HPV DNA detected and most (81.3%) had only 1 205 
HPV genotype persisting, Table 1. HPV-16 and/or HPV-18 DNA was present in the majority of SCC 206 
(82.8%) and AC (64.3%) cases and over half (56.2%) of CIN III samples, Table 2. Other HR HPV 207 
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genotypes were more prevalent in CIN I-III pathologies, and present in less than 10% of SCCs and AC 208 
cases. LR-HPV genotypes were most common in lower grade cervical lesions and absent in cervical 209 
cancer specimens, Table 2. Almost a third (32.0%) of all pathologies were HPV negative. The 210 
distribution of HPV genotypes detected within each cervical pathology is detailed in Table 3. The 211 
current HPV vaccination genotypes (HR-HPV 16 and or HR-HPV 18) were found in at least 82.8% of 212 
women with SCC of the cervix. For cervical SCC, HPV-16 (n=51/64), HPV-18 (n=3/64), HPV-45 213 
(n=3/64) and HPV-52 (n=5/64) made up 96% of the HPV positive samples. HPV-16 was the most 214 
common HPV detected across all cervical pathologies, except for AC where HPV-18 predominated 215 
with HPV-16, HPV-51 and HPV-54 making up the remaining HPV genotypes present, Table 3.  216 
 217 
Age-specific prevalence for HPV infection:  218 
The pathological distribution of samples by five-year age group is shown in Table 4. The mean age of 219 
women included in the study was 32 years (range 16-93 years, standard deviation (SD) 9.4 years) and 220 
significantly differed between histopathological groups (P <0.001). In total, 375 samples were from 221 
women aged 24 years and under, 887 from women aged 25 to 34 years and 565 samples from those 222 
aged 35 years and over. CIN I was more common in younger women and CIN II and CIN III most 223 
common in those aged 25-29 years. SCC was most common in women aged 35-39 years, Table 4.  224 
 225 
The number of HPV genotypes decreased with increasing age, with just over half (51.0%) of all HPV 226 
infections found in tissue from women aged between 25-29 years, Table 1. Most tissue samples had 227 
a single HPV genotype and this was more common in those aged over 60 years. Five or more HPV 228 
genotypes were detected in some women but this was largely limited to those aged under the age of 229 
40 years, Table 1. 41.7% of women with cervical pathology had HPV-16 or HPV-18 detected, and the 230 
highest proportion HPV 16/18 positive were over the age of 65 years, Table 2. Other HR-HPV 231 
genotypes were more common in younger women, particularly those aged 35-39 years. LR-HPV 232 
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genotypes were most common in those aged 55-59 years, with women over the age of 60 years 233 
having no LR-HPV genotypes detected, Table 2.  234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
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DISCUSSION:  259 
This is the largest population-based study investigating the HPV genotype distribution in women 260 
with CIN I-III and cervical SCC and AC in NI. The overall prevalence of any HPV in SCC samples was 261 
92.2% and was 68.0% across all cervical samples investigated. HR-HPV was detected in 64.8% of all 262 
samples with HPV-16 being the most common HPV genotype identified, which is consistent with that 263 
described elsewhere in CIN cases across Europe in countries such as Spain, France and Germany 264 
[García-Espinosa et al, 2012; Monsonego et al, 2012; de Jonge et al, 2013; Leinonen et al, 2013; 265 
Rössler et al, 2013] and in invasive disease internationally [Bosch et al, 2008; de Sanjose et al, 2010; 266 
Li et al, 2011]. As previously reported the prevalence of HPV increased through CIN I-III lesions in NI 267 
[Anderson et al, 2013] from 48.1% in CIN I to 81.3% in CIN III cases.  Most HPV positive samples had 268 
HR-HPV genotypes with HPV-16 and/or HPV-18 present in 20.6%, 35.3% and 56.2% of CIN I-III cases 269 
respectively.     270 
 271 
In an examination of FFPE tissue from more than 6,000 women from 17 European countries using 272 
the SPF10-LiPA25 assay, including data from neighbouring Scotland, Ireland and Wales, Tjalma et al 273 
found HPV-16 was the most frequent HPV type detected in both CIN and invasive cervical cancer 274 
[Tjalma et al, 2013]. HPV-16 and/ or HPV-18 prevalence (among HPV positive cases) was reported as 275 
45.8% in CIN II and 67.3% in CIN III cases [Tjalma et al, 2013], slightly higher than the current study. 276 
The authors reported HPV-31, 33, 35, 51, 52, 58 and 68 as the most frequently detected genotypes 277 
in women with high-grade CIN lesions. Apart from HPV-16, we similarly found that HPV-18, 31, 33, 278 
45, 51 and 52 were the most common genotypes identified in high grade lesions. Building on 279 
previous meta-analyses of type-specific HPV prevalence worldwide by specific grades of cervical 280 
disease [Clifford et al, 2003, 2005; Smith et al, 2007; Li et al, 2011] Guan et al in a further meta-281 
analysis of 423 studies (144 of which were from Europe) using PCR assays based on various primers 282 
among cell or biopsy/tissue cervical diagnoses also showed an increasing HPV prevalence with 283 
increasing severity of cervical disease, with HPV-16 the most frequently detected HR-HPV type in all 284 
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grades [Guan et al, 2012]. The prevalence (including HPV negative cases in the denominator) of HPV-285 
16 was 27.6%, 39.8% and 58.2% and HPV-18 prevalence 9.0%, 10.0% and 7.4% in CIN I to CIN III 286 
cases respectively [Guan et al, 2012], again higher than the estimates reported in the present study, 287 
variation which may have arisen from methodological differences in HPV detection techniques. The 288 
majority of SCCs (92.2%) in the present study were HPV positive, this is in accordance with the 289 
proportions of invasive cervical cancers (the majority of which were SCCs) testing HPV positive in 290 
other countries of the UK [Mesher et al, 2014], Sweden, Spain Italy and eastern Europe [Du et al, 291 
2011; Alemany et al, 2012; Giorgi Rossi et al, 2012; Guan et al, 2012; Piana et al, 2013; Pista et al, 292 
2013; Škamperle et al, 2013; Tjalma et al, 2013; Kjær et al, 2014; Simanaviciene et al, 2014].       293 
 294 
There were only 14 cases of AC included in the current investigation, and therefore our study is likely 295 
underpowered to investigate HPV prevalence in this subgroup. Of note however, HPV-18 was the 296 
most common HPV type in AC cases with a prevalence of 42.9% in the current study, akin to a recent 297 
Scottish estimate of 44.0% (among HPV positive cases) [Powell et al, 2013] which examined HPV 298 
DNA in FFPE tissue detected using the SPF10-DEIA/LiPA25-PCR assay. The prevalence of HPV-16 299 
and/or HPV-18 was 64.3%, lower than reported in an English multi-site investigation of HPV DNA in 300 
cervical cytology and cervical cancer biopsies using the Roche Linear array typing system (81.9%, 301 
among HPV positive cases) [Howell-Jones et al, 2010] and among AC cases from other European 302 
studies (94.6%)  [Tjalma et al, 2013]; perhaps due to a lower HPV-18 rate. 303 
 304 
The number of HPV genotypes detected in the current study varied across pathological grade, with 305 
the lowest percentage of single genotypes (31.0%) in CIN I lesions and the highest proportion 306 
(81.3%) in cervical SCCs, indicative that a single HPV genotype remains persistent in patients that 307 
progress. Although HPV persistence has been shown to vary by geographical region, HPV-16, 18, 31, 308 
33, 45, 52 and 58 are the most persistent HPV genotypes reported among women with invasive 309 
cervical cancer [Bernard et al, 2013; Rositch et al, 2013]. The most frequent single genotypes in the 310 
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current investigation in SCCs were HPV 16, 18, 45, 31, 39 and HPV 52. Notably, this profile includes 311 
several HPV genotypes which are not currently incorporated in the present HPV vaccine programme. 312 
These should be considered in the next generation of anti-HPV vaccines. In line with the UK HPV 313 
vaccination programme, in September 2012 NI began using the quadrivalent vaccine Gardasil® 314 
(Gardasil, Sanofi Pasteur MSD), with a relatively high uptake of 86.8% for all three doses in girls aged 315 
12-13 years [HSC Public Health Agency Northern Ireland, 2014]. Markov modelling has shown that 316 
the UK HPV vaccination programme would require 80% uptake to have a reduction of 66% in the 317 
prevalence of high-grade precancerous lesions and a 76% reduction in cervical cancer deaths [Kohli 318 
et al, 2007]. Therefore the HPV genotypes covered by the current HPV vaccination programme will 319 
lower the prevalence of HPV 16/18, as has already been evidenced in Scotland [Kavanagh et al, 320 
2014], and should prevent the majority of cervical cancers in NI. The formerly used bivalent vaccine 321 
(Cervarix®) offers some cross-protection for HPV genotypes of the A7 species including HR HPV-31, 322 
33 and 45 [Paavonen et al, 2009; Malagón et al, 2012; De Vincenzo et al, 2013; Verdenius et al, 323 
2013]. The potential effects of vaccine cross protection against other oncogenic non-target 324 
genotypes should also be considered when conducting future cost-benefit analyses.  325 
 326 
The principal strength of this study is its size and population-based design. The study was able to 327 
report the identification of high and low-risk HPV genotypes as well as the prevalence of multiple 328 
HPV infections. When comparing the HPV prevalence between countries it is important to consider 329 
that variations in HPV positivity may be explained by differences in the quality and type of samples 330 
analyzed (biopsies, surgical specimens or fresh tissue), as well as the methods of HPV detection and 331 
assessment.  332 
 333 
While it is frequently reported that 99.7% of cervical SCCs are HPV positive [Walboomers et al, 334 
1999],  women have been shown to have cervical disease without testing HPV positive using current 335 
methods. In a pooled analysis of 3 large Italian case series using three different PCR methods, 24 336 
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(4.2%) of 574 invasive cervical cancers were found to be ‘true’ HPV negative cases [Giorgi Rossi et al, 337 
2012]. Similarly, Tjalma et al in large-scale data from 17 European countries found that 8.2% of 338 
invasive cervical cancers were HPV negative [Tjalma et al, 2013]. HPV-negative carcinoma, if it exists 339 
at all, is likely to be rare. In the present study 10/78 invasive cervical cancers (12.8%) tested HPV 340 
negative. Although other aetiologic factors, such as mutations within the p53 gene, may explain 341 
some HPV negative cases [Fogel et al, 1995] the potential for false negative results arising from 342 
differences in analytic sensitivity for different HPV types particularly in the presence of multiple 343 
infections, low titer or copy number of HPV DNA and  inadequacy of the specimen should be 344 
carefully considered. For instance, HPV genotyping analysis in the present study was undertaken 345 
using the Roche linear array detection kit. Importantly, this assay uses PGMY L1 consensus primers 346 
to amplify a 450-bp fragment. As it is well known that formaldehyde fixation provides low yields of 347 
extractable DNA due to protein cross-linking and strand cleavage, such a large amplicon size 348 
provides the potential for false negative results on FFPE tissue. Whilst the detection of HPV in fresh 349 
frozen tissue appears superior [Odida et al, 2010], this would have been difficult to acquire and 350 
process in a large population-based study such as this.  351 
 352 
In conclusion, HPV-16 was identified as the main HPV genotype associated with cervical disease in 353 
NI, contributing to around 83.0% of the cervical SCCs investigated.  Provided there is sustained high 354 
HPV vaccine coverage in NI, the current HPV vaccination programme should prevent the majority of 355 
cervical cancers but coverage of other HR-HPV genotypes with high prevalence and oncogenic 356 
potential including HPV-31, 39, 45 and 52 and the potential influence of cross protection, should be 357 
considered in any future polyvalent vaccines.  358 
 359 
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FIGURE LEGENDS:  368 
Figure 1: Flowchart of sample selection and eligibility  369 
Figure 2: Overall HPV genotype profile denoting the prevalence of single and multiple HPV infections 370 
 371 
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Table 1:  Percentage distribution of the number of HPV genotypes detected by 
pathological subtype and 5-year age group. 
 
 Number of HPV Genotypes detected (% of each pathology)  
Pathology HPV negative 1 2 3 4 5 or more Total n (%) 
CIN I 
 
283 (51.9) 169 (31.0) 63 (11.6) 19 (3.5) 9 (1.7) 2 (0.4) 545 (100.0) 
CIN II 
 
145 (34.1) 217 (51.1) 46 (10.8) 15 (3.5) 1 (0.2) 1 (0.2) 425 (100.0) 
CIN III 
 
146 (18.7) 462 (59.3) 129 (16.6) 32 (4.1) 4 (0.5) 6 (0.8) 779 (100.0) 
SCC 
 
5 (7.8) 52 (81.3) 6 (9.4) 1 (1.6) 0 (0.0) 0 (0.0) 64 (100.0) 
AC 5 (35.7) 8 (57.1) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0) 14 (100.0) 
Age group (yrs) HPV negative 1 2 3 4 5 or more Total n (%) 
Under 25 115 (30.7) 172 (45.9) 64 (17.1) 18 (4.8) 3 (0.8) 3 (0.8) 375 (100.0) 
25-29 152 (28.7) 270 (51.0) 79 (14.9) 21 (4.0) 6 (1.1) 1 (0.2) 529 (100.0) 
30-34 110 (30.7) 186 (52.0) 44 (12.3) 14 (3.9) 1 (0.3) 3 (0.8) 358 (100.0) 
35-39 74 (33.3) 119 (53.6) 23 (10.4) 4 (1.8) 1 (0.5) 1 (0.5) 222 (100.0) 
40-44 51 (33.8) 77 (51.0) 16 (10.6) 6 (4.0) 1 (0.7) 0 (0.0) 151 (100.0) 
45-49 41 (44.6) 39 (42.4) 9 (9.8) 2 (2.2) 1 (1.1) 0 (0.0) 92 (100.0) 
50-54 24 (49.0) 17 (34.7) 6 (12.2) 1 (2.0) 1 (2.0) 0 (0.0) 49 (100.0) 
55-59 10 (35.7) 13 (46.4) 3 (10.7) 1 (3.6) 0 (0.0) 1 (3.6) 28 (100.0) 
60-64 3 (33.3) 6 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 (100.0) 
65+ 4 (28.6) 9 (64.3) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0) 14 (100.0) 
TOTAL 584 (32.0) 908 (49.7) 244 (13.4) 68 (3.7) 14 (0.8) 9 (0.5) 1,827 (100.0) 
CIN = Cervical Intraepithelial Neoplasia (grades I-III), SCC = Squamous cell carcinoma, AC = Adenocarcinoma 
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Table 2: Type of HPV genotypes detected by cervical pathology and 5-year age group. 
 
 
HPV-16 
and or 
HPV-18 
n (%) 
Other High-risk HPV 
genotypes* 
 
n (%) 
Low risk HPV 
genotypes 
Only 
n (%) 
HPV negative 
 
 
n (%) 
Total 
Pathology 
 
n (%) 
CIN I 112 (20.6) 121 (22.2) 29 (5.3) 283 (51.9) 545 (100.0) 
CIN II 150 (35.3) 110 (25.9) 20 (4.7) 145 (34.1) 425 (100.0) 
CIN III 438 (56.2) 184 (23.6) 11 (1.4) 146 (18.7) 779 (100.0) 
SCC 53 (82.8) 6 (9.4) 0 (0.0) 5 (7.8) 64 (100.0) 
AC 9 (64.3) 1 (7.1) 0 (0.0) 5 (35.7) 14 (100.0) 
Age group (yrs)      
Under 25 154 (41.1) 93 (24.8) 13 (3.5) 115 (30.7) 375 (100.0) 
25-29 237 (44.8) 127 (24.0) 13 (2.5) 152 (28.7) 529 (100.0) 
30-34 151 (42.2) 82 (22.9) 15 (4.2) 110 (30.7) 358 (100.0) 
35-39 84 (37.8) 59 (26.6) 5 (2.3) 74 (33.3) 222 (100.0) 
40-44 59 (39.1) 36 (23.8) 5 (3.3) 51 (33.8) 151 (100.0) 
45-49 34 (37.0) 12 (13.0) 5 (5.4) 41 (44.6) 92 (100.0) 
50-54 18 (36.7) 5 (10.2) 2 (4.1) 24 (49.0) 49 (100.0) 
55-59 12 (42.9) 4 (14.3) 2 (7.1) 10 (35.7) 28 (100.0) 
60-64 4 (44.4) 2 (22.2) 0 (0.0) 3 (33.3) 9 (100.0) 
65+ 9 (64.3) 1 (7.1) 0 (0.0) 4 (28.6) 14 (100.0) 
TOTAL n (%) 
762 
(41.7) 
421 (23.0) 60 (3.3) 584 (32.0) 1,827 (100.0) 
* Including high-risk HPV genotypes other than HPV 16/18 i.e.: HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. 
CIN = Cervical Intraepithelial Neoplasia (grades I-III), SCC = Squamous cell carcinoma, AC = Adenocarcinoma 
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Table 3: HPV genotype distribution by cervical pathology 
 Cervical histology  
HPV genotype AC CIN I CIN II CIN III SCC Total 
HPV 16 3 (21.4) 87 (16.0) 136 (32.0) 407 (52.3) 51 (79.7) 684 (37.4) 
HPV 31 0 (0.0) 35 (6.4) 29 (6.8) 84 (10.8) 2 (3.1) 150 (8.2) 
HPV 52 0 (0.0) 22 (4.0) 33 (7.8) 65 (8.3) 5 (7.8) 125 (6.8) 
HPV 18 6 (42.9) 29 (5.1) 17 (4.0) 39 (5.0) 3 (4.7) 93 (5.1) 
HPV 33 0 (0.0) 18 (3.3) 15 (3.5) 58 (7.5) 0 (0.0) 91 (5.0) 
HPV 51 1 (7.1) 17 (3.1) 25 (5.9) 28 (3.6) 0 (0.0) 71 (3.9) 
HPV 45 0 (0.0) 14 (2.6) 10 (2.4) 31 (4.0) 3 (4.7) 58 (3.2) 
HPV 39 0 (0.0) 20 (3.7) 12 (2.8) 14 (1.8) 1 (1.6) 47 (2.6) 
HPV 58 0 (0.0) 11 (2.0) 13 (3.1) 17 (2.2) 0 (0.0) 41 (2.2) 
HPV 66 0 (0.0) 22 (4.0) 6 (1.4) 10 (1.3) 0 (0.0) 38 (2.1) 
HPV 35 0 (0.0) 9 (1.7) 12 (2.8) 16 (2.1) 0 (0.0) 37 (2.0) 
HPV 59 0 (0.0) 14 (2.6) 8 (1.9) 8 (1.0) 0 (0.0) 30 (1.6) 
HPV 56 0 (0.0) 18 (3.3) 3 (0.7) 5 (0.6) 0 (0.0) 26 (1.4) 
HPV 6 0 (0.0) 7 (1.3) 9 (2.1) 9 (1.2) 0 (0.0) 25 (1.4) 
HPV 73 0 (0.0) 9 (1.7) 6 (1.4) 8 (1.0) 0 (0.0) 23 (1.3) 
HPV 53 0 (0.0) 9 (1.7) 5 (1.2) 5 (0.6) 0 (0.0) 19 (1.0) 
HPV 70 0 (0.0) 4 (0.7) 4 (0.9) 9 (1.2) 0 (0.0) 17 (0.9) 
HPV 42 0 (0.0) 9 (1.7) 2 (0.5) 3 (0.4) 0 (0.0) 14 (0.8) 
HPV 61 0 (0.0) 6 (1.1) 1 (0.2) 7 (0.9) 0 (0.0) 14 (0.8) 
HPV 54 1 (7.1) 2 (0.4) 3 (0.7) 5 (0.8) 0 (0.0) 12 (0.7) 
HPV 11 0 (0.0) 5 (0.9) 2 (0.5) 4 (0.5) 0 (0.0) 11 (0.6) 
HPV 68 0 (0.0) 4 (0.7) 5 (1.2) 2 (0.3) 0 (0.0) 11 (0.6) 
HPV CP6108 0 (0.0) 4 (0.7) 0 (0.0) 6 (0.8) 0 (0.0) 10 (0.6) 
HPV 82 0 (0.0) 1 (0.2) 0 (0.0) 8 (1.0) 0 (0.0) 9 (0.5) 
HPV 62 0 (0.0) 2 (0.4) 1 (0.2) 4 (0.5) 0 (0.0) 7 (0.4) 
HPV 84 0 (0.0) 3 (0.6) 2 (0.5) 2 (0.3) 0 (0.0) 7 (0.4) 
HPV 81 0 (0.0) 6 (1.1) 0 (0.0) 1 (0.1) 0 (0.0) 7 (0.4) 
HPV 69 0 (0.0) 2 (0.4) 1 (0.2) 2 (0.3) 0 (0.0) 5 (0.3) 
HPV 55 0 (0.0) 3 (0.6) 1 (0.2) 0 (0.0) 0 (0.0) 4 (0.2) 
HPV 83 0 (0.0) 2 (0.4) 1 (0.2) 1 (0.1) 0 (0.0) 4 (0.2) 
HPV is39 0 (0.0) 0 (0.0) 2 (0.5) 1 (0.1) 0 (0.0) 3 (0.2) 
HPV 67 0 (0.0) 3 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.2) 
HPV 40 0 (0.0) 1 (0.2) 0 (0.0) 1 (0.1) 0 (0.0) 2 (0.11) 
HPV 26 0 (0.0) 1 (0.2) 0 (0.0) 1 (0.1) 0 (0.0) 2 (0.1) 
HPV 64 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 
HPV 72 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
HPV 71 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
TOTAL 11 (78.5) 400 (73.6) 364 (85.6) 861 (110.8) 65 (101.6) 1701 (93.3)* 
AC = adenocarcinoma, CIN = Cervical Intraepithelial Neoplasia (grades I-III), SCC = Squamous Cell Carcinoma  
* This figure does not add up to 1,243 (i.e.: the number HPV positive) as several patients may have had multiple HPV genotypes on testing 
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Table 4: Pathological distribution of cohort (numbers of cases) by five-year age group                                                          
 
 
 
Mean age 
years (± SD; range) 
AGE (years) n (%) 
PATHOLOGY n (%)  <25 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+ TOTAL 
CIN I 32 (10; 16-69) 144 (26.4)  136 (25.0) 82 (15.1) 55 (10.1) 51 (9.4) 42 (7.7) 19 (3.5) 11 (2.0) 3 (0.6) 2 (0.4) 545 (100.0) 
CIN II 32 (9; 18-80) 83 (19.5) 120 (28.2) 92 (21.7) 51 (12.0) 40 (9.4) 17 (4.0) 11 (2.6) 6 (1.4) 1 (0.2) 4 (0.9) 425 (100.0) 
CIN III 31 (8; 18-64) 146 (18.7) 268 (34.4) 169 (21.7) 94 (12.1) 53 (6.8) 27 (3.5) 12 (1.5) 7 (0.9) 3 (0.4) 0 (0.0) 779 (100.0) 
SSC 43 (14; 23-93) 1 (1.6) 3 (4.7) 12 (18.8) 19 (29.7) 7 (10.9) 5 (7.8) 7 (10.9) 3 (4.7) 1 (1.6) 6 (9.4) 64 (100.0) 
AC 42 (16; 23-73) 1 (7.1) 2 (14.3) 3 (21.4) 3 (21.4) 0 (0.0) 1 (7.1) 0 (0.0) 1 (7.1) 1 (7.1) 2 (14.3) 14 (100.0) 
TOTAL n (%)  375 (20.5) 529 (28.9) 358 (19.6) 222 (12.2) 151 (8.3) 92 (5.0) 49 (2.7) 28 (1.5) 9 (0.5) 14 (0.8) 1,827 (100.0) 
CIN = Cervical Intraepithelial Neoplasia (grades I-III), SCC = Squamous Cell Carcinoma, AC= Adenocarcinoma  
±SD = Standard deviation  
N.B.: Please note that certain pathological groups were overrepresented in this study, so the proportions above may not be a true reflection of the distribution of cervical pathologies within each age category in Northern Ireland. 
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